Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Accenture
Citi
Harvard Business School
US Army
Merck
Chubb
McKinsey
Queensland Health
Mallinckrodt

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,403,609

« Back to Dashboard

Which drugs does patent 6,403,609 protect, and when does it expire?

Patent 6,403,609 protects ILEVRO and is included in one NDA.

This patent has thirty-one patent family members in eighteen countries.
Summary for Patent: 6,403,609
Title: Ophthalmic compositions containing galactomannan polymers and borate
Abstract:The present invention is directed to ophthalmic compositions containing a gelling amount of a combination of galactomannan polysaccharides and borates. The compositions gel or partially gel upon administration to the eye. The present invention also discloses methods of topical ophthalmic administration of the compositions of the eye.
Inventor(s): Asgharian; Bahram (Arlington, TX)
Assignee: Alcon Manufacturing, Ltd. (Fort Worth, TX)
Application Number:09/423,762
Patent Claim Types:
see list of patent claims
Composition; Use; Delivery;

Drugs Protected by US Patent 6,403,609

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp ILEVRO nepafenac SUSPENSION/DROPS;OPHTHALMIC 203491-001 Oct 16, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,403,609

PCT Information
PCT FiledJuly 17, 1998PCT Application Number:PCT/US98/14596
PCT Publication Date:February 11, 1999PCT Publication Number: WO99/06023

Non-Orange Book US Patents Family Members for Patent 6,403,609

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,486,138 Ophthalmic compositions containing galactomannan polymers and borate ➤ Subscribe
6,583,124 Ophthalmic compositions containing galactomannan polymers and borate ➤ Subscribe
7,169,767 Ophthalmic compositions containing galactomannan polymers and borate ➤ Subscribe
6,838,449 Ophthalmic compositions containing galactomannan polymers and borate ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,403,609

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 577751 ➤ Subscribe
Portugal 1348427 ➤ Subscribe
Portugal 999825 ➤ Subscribe
Luxembourg 92301 ➤ Subscribe
Japan 2007197461 ➤ Subscribe
Japan 4673339 ➤ Subscribe
Japan 3979783 ➤ Subscribe
Japan 2003528797 ➤ Subscribe
European Patent Office 1348427 ➤ Subscribe
European Patent Office 0999825 ➤ Subscribe C300622 Netherlands ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Federal Trade Commission
Covington
UBS
Farmers Insurance
Dow
Cerilliant
Daiichi Sankyo
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot